Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management

Via the PhilRx Patient Access Platform, patients can now access Teva Pharmaceuticals’ Digihaler® family of inhalers

... | June 6, 2023

Related Keywords

Proair Digihaler ,Manny Montalvo ,Armonair Digihaler ,Deepak Thomas ,Airduo Digihaler ,Teva Digihaler ,Digital Health Innovation ,Teva Pharmaceuticals ,Teva Pharmaceutical ,Teva Pharmaceutical Industries Ltd ,Phil Inc ,Upper Airway Symptoms ,Philrx Patient Access ,Philrx Patient Access Platform ,Digital Health ,Chief Executive Officer ,Air Digihaler Indications ,Air Digihaler ,Inhalation Powder ,Discontinue Proair Digihaler ,Anti Inflammatory Agents ,Not Exceed Recommended Dose ,Oxidase Inhibitors ,Tricyclic Antidepressants ,Prescribing Information ,Duo Digihaler Indications ,Duo Digihaler ,Safety Information ,Acute Episodes ,Systemic Corticosteroid Therapy ,Adrenal Suppression ,Including Anaphylaxis ,Discontinue Armonair Digihaler ,Bone Mineral Density ,Churg Strauss Syndrome ,Silicon Valley ,Pharmaceutical Industries ,Teva Pharmaceutical Industries Limited Stock Exchange ,News ,Information ,Press Release ,Cia ,The ,Hilrx ,Patient ,Access ,Patients ,Han ,Dow ,Eva ,Family ,F Teva Us8816242098 ,